ArticleCanadian journal of gastroenterology = Journal canadien de gastroenterologie2007
Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients.
Article in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Osteoporosis drug therapy strategies in the setting of disease-modifying agents for autoimmune disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013Pooled it
- Adalimumab Therapy Has a Beneficial Effect on Bone Metabolism in Patients with Crohn's Disease.Digestive diseases and sciences · 2015Trial
- Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease.Intestinal research · 2025Review
- Osteoporosis Complications in Crohn's Disease Patients: Factors, Pathogenesis, and Treatment Outlines.Cureus · 2021Review
- A Vicious Cycle of Osteosarcopeniain Inflammatory Bowel Diseases-Aetiology, Clinical Implications and Therapeutic Perspectives.Nutrients · 2021Review
- Nutrients in the Prevention of Osteoporosis in Patients with Inflammatory Bowel Diseases.Nutrients · 2020Review
- Bone mineral density and inflammatory bowel disease severity.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2017Article
- Premenopausal Osteoporosis.Endocrinology and metabolism clinics of North America · 2017Review
- Risk factors for osteoporosis in inflammatory bowel disease patients.World journal of gastrointestinal pathophysiology · 2015Review
- Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.European journal of endocrinology · 2015Review
- Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.World journal of gastroenterology · 2015Article
- Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C.Digestive diseases and sciences · 2015Article
- Pathological fractures in paediatric patients with inflammatory bowel disease.European journal of pediatrics · 2014Review
- Evaluation and management of the premenopausal woman with low BMD.Current osteoporosis reports · 2013Article
- Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases.Arthritis care & research · 2013Article
- Osteoporosis in young adults: pathophysiology, diagnosis, and management.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012Review
- Effects of anti-tumor necrosis factor α agents on bone.Current opinion in rheumatology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with Crohn's disease (CD) have a high risk of developing osteoporosis, but the mechanisms underlying bone mass loss are unclear. Elevated proinflammatory cytokines, such as tumour necrosis factor-alpha (TNFalpha), have been implicated in the pathogenesis of bone resorption.
aimTo assess whether suppression of TNFalpha with infliximab treatment has a beneficial effect on lumbar bone mass.
methodsAdult CD patients who had received infliximab treatment, and who underwent lumbar densitometric evaluation before and during treatment, were selected. Adult CD patients who had never received infliximab treatment were selected as controls. Information regarding age, sex, weight, duration of CD, use of glucocorticoids and bisphosphonates, and signs of disease activity between both densitometric measurements were collected.
resultsData from 45 patients were analyzed. The control group (n=30, mean [+/- SD] 26.7+/-9 years of age) had a significantly higher increase in body weight between both evaluations (6.26%+/-8%) than the infliximab group (n=15, 30.6+/-13 years), which had an increase of 0.3%+/-7.4%. There was a strong correlation between the final weight and lumbar bone mineral content (BMC) in both groups. The infliximab group had a significant increase in lumbar bone area (4.15%+/-6.6%), BMC (12.8%+/-13.6%) and bone mineral density (8.13%+/-7.7%) between both evaluations (interval 22.6+/-11 months) compared with the control group. The increase in BMC in patients who had received infliximab treatment was significant when compared with control patients who had received glucocorticoids (n=8) or had evidence of disease activity (n=13).
conclusionInfliximab therapy improved lumbar bone mass independent of nutritional status. This finding suggests that TNFalpha plays a role in bone loss in CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.